Literature DB >> 16256156

Biological and molecular characterization of a canine hemangiosarcoma-derived cell line.

Douglas H Thamm1, Erin B Dickerson, Nasim Akhtar, Rachel Lewis, Robert Auerbach, Stuart C Helfand, E Gregory MacEwen.   

Abstract

Canine hemangiosarcoma (HSA) is a devastating disease. Investigation of novel therapies has been limited by the limited availability of canine HSA-derived cell lines. We report the development of a canine HSA-derived cell line, DEN-HSA, which recapitulates features of angiogenic endothelium. DEN-HSA cells were derived from a spontaneous HSA arising in the kidney of a dog. DEN-HSA displayed surface molecules distinctive of endothelial histogenesis, including factor VIII-related antigen, ICAM-1 and alpha(v)beta3 integrin. In vitro, DEN-HSA formed microvascular tube-like structures on Matrigel, and proliferated in response to a variety of angiogenic growth factors. The cells expressed mRNA and protein specific for bFGF and its receptors, and VEGF and its receptors, among others. DEN-HSA conditioned medium evoked a marked angiogenic response in a murine corneal pocket assay, indicating potent proangiogenic activity of substances secreted by this cell line. This research confirms the DEN-HSA cell line as endothelial in origin, suggests the presence of angiogenic growth factor autocrine loops, and offers the potential to utilize DEN-HSA cells for the study of novel therapies that modulate endothelial proliferation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16256156     DOI: 10.1016/j.rvsc.2005.09.005

Source DB:  PubMed          Journal:  Res Vet Sci        ISSN: 0034-5288            Impact factor:   2.534


  16 in total

1.  Effects of inhibitors of vascular endothelial growth factor receptor 2 and downstream pathways of receptor tyrosine kinases involving phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin or mitogen-activated protein kinase in canine hemangiosarcoma cell lines.

Authors:  Mami Adachi; Yuki Hoshino; Yusuke Izumi; Hiroki Sakai; Satoshi Takagi
Journal:  Can J Vet Res       Date:  2016-07       Impact factor: 1.310

2.  Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20.

Authors:  Kipp Weiskopf; Katie L Anderson; Daisuke Ito; Peter J Schnorr; Hirotaka Tomiyasu; Aaron M Ring; Kristin Bloink; Jem Efe; Sarah Rue; David Lowery; Amira Barkal; Susan Prohaska; Kelly M McKenna; Ingrid Cornax; Timothy D O'Brien; M Gerard O'Sullivan; Irving L Weissman; Jaime F Modiano
Journal:  Cancer Immunol Res       Date:  2016-11-14       Impact factor: 11.151

3.  Imatinib and Dasatinib Inhibit Hemangiosarcoma and Implicate PDGFR-β and Src in Tumor Growth.

Authors:  Erin B Dickerson; Kevin Marley; Wade Edris; Jeffrey W Tyner; Vidya Schalk; Valerie Macdonald; Marc Loriaux; Brian J Druker; Stuart C Helfand
Journal:  Transl Oncol       Date:  2013-04-01       Impact factor: 4.243

4.  Role of monocyte recruitment in hemangiosarcoma metastasis in dogs.

Authors:  D P Regan; A Escaffi; J Coy; J Kurihara; S W Dow
Journal:  Vet Comp Oncol       Date:  2016-10-25       Impact factor: 2.613

5.  Gene expression profiling identifies inflammation and angiogenesis as distinguishing features of canine hemangiosarcoma.

Authors:  Beth A Tamburini; Tzu L Phang; Susan P Fosmire; Milcah C Scott; Susan C Trapp; Megan M Duckett; Sally R Robinson; Jill E Slansky; Leslie C Sharkey; Gary R Cutter; John W Wojcieszyn; Donald Bellgrau; Robert M Gemmill; Lawrence E Hunter; Jaime F Modiano
Journal:  BMC Cancer       Date:  2010-11-09       Impact factor: 4.430

6.  Hemangiosarcoma and its cancer stem cell subpopulation are effectively killed by a toxin targeted through epidermal growth factor and urokinase receptors.

Authors:  Jill T Schappa; Aric M Frantz; Brandi H Gorden; Erin B Dickerson; Daniel A Vallera; Jaime F Modiano
Journal:  Int J Cancer       Date:  2013-04-25       Impact factor: 7.396

7.  Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature.

Authors:  Melissa C Paoloni; Anita Tandle; Christina Mazcko; Engy Hanna; Stefan Kachala; Amy Leblanc; Shelley Newman; David Vail; Carolyn Henry; Douglas Thamm; Karin Sorenmo; Amin Hajitou; Renata Pasqualini; Wadih Arap; Chand Khanna; Steven K Libutti
Journal:  PLoS One       Date:  2009-03-30       Impact factor: 3.240

8.  Establishment of canine hemangiosarcoma xenograft models expressing endothelial growth factors, their receptors, and angiogenesis-associated homeobox genes.

Authors:  Atsushi Kodama; Hiroki Sakai; Satoko Matsuura; Mami Murakami; Atsuko Murai; Takashi Mori; Kouji Maruo; Tohru Kimura; Toshiaki Masegi; Tokuma Yanai
Journal:  BMC Cancer       Date:  2009-10-14       Impact factor: 4.430

9.  Gene expression profiles of sporadic canine hemangiosarcoma are uniquely associated with breed.

Authors:  Beth A Tamburini; Susan Trapp; Tzu Lip Phang; Jill T Schappa; Lawrence E Hunter; Jaime F Modiano
Journal:  PLoS One       Date:  2009-05-20       Impact factor: 3.240

10.  Constitutive phosphorylation of the mTORC2/Akt/4E-BP1 pathway in newly derived canine hemangiosarcoma cell lines.

Authors:  Atsuko Murai; Samah Abou Asa; Atsushi Kodama; Akihiro Hirata; Tokuma Yanai; Hiroki Sakai
Journal:  BMC Vet Res       Date:  2012-07-29       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.